The science of rheumatoid arthritis: a prelude

door Smolen, Josef S
Gepubliceerd in 2005

Expanding the frontiers of therapy

door Smolen, Josef S
Gepubliceerd in 2006

Therapy of systemic lupus erythematosus: a look into the future

door Smolen, Josef S
Gepubliceerd in 2002

Greetings from the editor

door Smolen, Josef S
Gepubliceerd in Ann Rheum Dis (2021)

SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus

door Aringer, Martin, Smolen, Josef S
Gepubliceerd in 2003

The role of tumor necrosis factor-alpha in systemic lupus erythematosus

door Aringer, Martin, Smolen, Josef S
Gepubliceerd in 2008

Developments in the clinical understanding of rheumatoid arthritis

door Smolen, Josef S, Aletaha, Daniel
Gepubliceerd in 2009

Infliximab: 12 years of experience

door Smolen, Josef S, Emery, Paul
Gepubliceerd in 2011

Autoantibodies in rheumatoid arthritis and their clinical significance

door Steiner, Günter, Smolen, Josef
Gepubliceerd in 2002

Correction: Interleukin-6: a new therapeutic target

door Smolen, Josef S, Maini, Ravinder N
Gepubliceerd in 2006

Interleukin-6: a new therapeutic target

door Smolen, Josef S, Maini, Ravinder N
Gepubliceerd in 2006

Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor

door Tan, Eng M., Smolen, Josef S.
Gepubliceerd in J Exp Med (2016)

The role of osteoprotegerin in arthritis

door Schett, Georg, Redlich, Kurt, Smolen, Josef S
Gepubliceerd in 2003

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs

door Radner, Helga, Smolen, Josef S, Aletaha, Daniel
Gepubliceerd in 2014

Response to ‘Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis’

door Vastesaeger, Nathan, Fautrel, Bruno, Smolen, Josef
Gepubliceerd in Arthritis Res Ther (2015)

Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials

door Aletaha, Daniel, Alasti, Farideh, Smolen, Josef S.
Gepubliceerd in Arthritis Res Ther (2015)

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruct...

door Smolen, Josef S, Avila, José C Martinez, Aletaha, Daniel
Gepubliceerd in 2011

Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients

door Radner, Helga, Alasti, Farideh, Smolen, Josef S., Aletaha, Daniel
Gepubliceerd in Arthritis Res Ther (2015)

The stressed synovium

door Schett, Georg, Tohidast-Akrad, Makiyeh, Steiner, Günter, Smolen, Josef
Gepubliceerd in 2001

Listeria-Associated Arthritis in a Patient Undergoing Etanercept Therapy: Case Report and Review of the Literature

door Schett, Georg, Herak, Petra, Graninger, Winfried, Smolen, Josef S., Aringer, Martin
Gepubliceerd in 2005